Search results
Showing 301 to 315 of 472 results for learning disabilities
NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .
Insertion of a magnetic bead band for faecal incontinence (HTG336)
Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.
View recommendations for HTG336Show all sections
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Secukinumab for treating active ankylosing spondylitis (TA407)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.
pregnant women (including gestational age)• people with learning disability or physical disability (or both)•...
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.